Successful therapy with anakinra in a patient with generalized pustular psoriasis carryingIL36RNmutations

Successful Treatment of Generalized Pustular Psoriasis With the Interleukin-1-Receptor Antagonist Anakinra: Lack of Correlation With IL1RN Mutations

(2013) Manuelle Viguier   ANNALS OF INTERNAL MEDICINE

Mutations in IL36RN in Patients with Generalized Pustular Psoriasis

(2013) Andreas Körber et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

DIRA, DITRA, and New Insights Into Pathways of Skin Inflammation

(2012) Edward W. Cowen   ARCHIVES OF DERMATOLOGY

IL-36 in psoriasis

(2012) JE Towne et al.   CURRENT OPINION IN PHARMACOLOGY

Alcohol consumption and psoriatic risk: A meta-analysis of case-control studies

(2012) Kun-Ju ZHU et al.   JOURNAL OF DERMATOLOGY

Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis

(2011) Alexandros Onoufriadis et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Interleukin-36 (IL-36) Ligands Require Processing for Full Agonist (IL-36α, IL-36β, and IL-36γ) or Antagonist (IL-36Ra) Activity

(2011) Jennifer E. Towne et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis

(2011) Slaheddine Marrakchi et al.   NEW ENGLAND JOURNAL OF MEDICINE